FDA Prescription Drug User Fee Program Could Go OIG Scrutiny
This article was originally published in The Tan Sheet
In addition to user fees, upcoming FDA reviews will focus on oversight of post-marketing requirements and information exchange in the drug supply chain.
You may also be interested in...
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Former CMS acting administrator Andy Slavitt says agency’s direction during Biden administration depends on nominee, but trust fund’s looming insolvency will be ‘an issue you can’t avoid.’ The president’s priorities around health equity, racial justice and mental health will make their way into CMS policy and demonstration models, Slavitt suggests.
Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.